Venom Evolution Lab, School of Biological Sciences, University of Queensland, St Lucia, QLD, 4072, Australia.
FaunaVet Wildlife Consultancy, Glass House Mountains, QLD, 4518, Australia.
Toxicol Lett. 2019 Mar 1;302:1-6. doi: 10.1016/j.toxlet.2018.11.015. Epub 2018 Nov 28.
Due to their potent coagulotoxicity, Australian elapid venoms are unique relative to non-Australian members of the Elapidae snake family. The majority of Australian elapids possess potent procoagulant venom, while only a few species have been identified as possessing anticoagulant venoms. The majority of research to-date has concentrated on large species with range distributions overlapping major city centres, such as brown snakes (Pseudonaja spp.) and taipans (Oxyuranus spp.). We investigated the venom from the poorly studied genus Denisonia and documented anticoagulant activities that were differentially potent on amphibian, avian, and human plasmas. Both species were potently anticoagulant upon amphibian plasma, consistent with these snakes preying upon frogs as their primary food source. While D. devisi was only relatively weakly active on avian and human plasma, D. maculata was potently anticoagulant to amphibian, avian, and human plasma. The mechanism of anticoagulant action was determined to be the inhibition of prothrombin activation by Factor Xa by blocking the formation of the prothrombinase complex. Fractionation of D. maculata venom followed by MS sequencing revealed that the toxins responsible were Group I phospholipase A. As no antivenom is produced for this species or its near relatives, we examined the ability of Seqirus Australian snake polyvalent antivenom to neutralise the anticoagulant effects, with this antivenom shown to be effective. These results contribute to the body of knowledge regarding adaptive evolution of venom, revealing a unique taxon-specific anticoagulant effect for D. devisi venom. These results also reveal the potential effects and mechanisms behind envenomation by the potently acting D. maculata venom on human plasma, while the discovery of the efficacy of an available antivenom provides information crucial to the design of snakebite management strategies.
由于其强大的凝血毒性,澳大利亚的眼镜蛇毒液相对于其他非澳大利亚眼镜蛇科的蛇类是独特的。大多数澳大利亚眼镜蛇都具有强大的促凝血毒液,而只有少数几种被认为具有抗凝血毒液。迄今为止,大多数研究都集中在具有广泛分布且与主要城市中心重叠的大型物种上,如棕色蛇(Pseudonaja spp.)和太攀蛇(Oxyuranus spp.)。我们研究了研究较少的 Denisonia 属的毒液,并记录了对两栖动物、鸟类和人类血浆具有不同效力的抗凝活性。这两个物种对两栖动物的血浆都具有强大的抗凝作用,这与这些蛇以青蛙为主要食物来源的情况相符。虽然 D. devisi 对鸟类和人类血浆的活性相对较弱,但 D. maculata 对两栖动物、鸟类和人类血浆具有强大的抗凝作用。抗凝作用的机制被确定为通过阻止凝血酶原酶复合物的形成来抑制因子 Xa 对凝血酶原的激活。D. maculata 毒液的分级分离和 MS 测序表明,负责这种毒素的是 I 组磷脂酶 A。由于没有针对该物种或其近亲的抗蛇毒血清,我们检查了 Seqirus 澳大利亚蛇多价抗蛇毒血清中和抗凝作用的能力,结果表明这种抗蛇毒血清是有效的。这些结果有助于了解毒液的适应性进化,揭示了 D. devisi 毒液的独特的分类特异性抗凝作用。这些结果还揭示了强效 D. maculata 毒液对人类血浆产生作用的潜在影响和机制,而发现有效的抗蛇毒血清提供了对蛇咬伤管理策略设计至关重要的信息。